Please login to the form below

Not currently logged in
Email:
Password:

Merck & Co’s Jürgen Polifka joins Cardiome

Will lead commercialisation in Europe of atrial fibrillation treatment Brinavess

Jürgen Polifka has left his role at Merck and Co to join Canada-based biopharma Cardiome as general manager, sales and marketing Europe.

Polifka was most recently regional marketing leader hospital care at Merck for a portfolio of products, including atrial fibrillation treatment Brinavess (vernakalant), which Cardiome is due to assume commercialisation responsibility for in Europe.

In total, Polifka spent more than 16 years at Merck, serving in several senior roles, such as product manager, marketing and sales manager, director hospital and specialty products and brand leader. During this time, he covered both infectious disease and cardiovascular care at different stages.

"We are extremely pleased to have Dr Polifka join Cardiome at such a critical time in its history," said Karim Lalji, Cardiome's chief commercial officer.

"His personal experience with Brinavess at MSD and deep understanding of the European hospital and cardiovascular markets will be invaluable as Cardiome assumes commercialisation responsibility for Brinavess in Europe."

9th April 2013

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics